Analysis of inflammatory cells in uveal melanoma after prior irradiation

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 360-369

  Vu, T H Khanh ^a   Bronkhorst, Inge H G ^a   Versluis, Mieke ^a   Marinkovic, Marina ^a   van Duinen, Sjoerd G ^a   Vrolijk, Johannes ^a   Luyten, Gregorius P M ^a   Jager, Martine J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; RUTHENIUM 106; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; INFLAMMATION; INFLAMMATORY CELL; IRRADIATION; MALE; MONOTHERAPY; PRIORITY JOURNAL; SPINDLE CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; UVEA MELANOMA; CELL COUNT; COMPARATIVE STUDY; ENUCLEATION; FOLLOW UP; MACROPHAGE; MELANOMA; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; UVEA TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CELL COUNT; EYE ENUCLEATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACROPHAGES; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY; UVEAL NEOPLASMS;

MLCS; MLOWN;

EID: 84874531371     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9424     Document Type: Article

References (38)

1. Virgili G, Gatta G, Ciccolallo L, et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114:2309-2315.
2. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:962-965.
3. Damato B. Does ocular treatment of uveal melanoma influence survival? Br J Cancer. 2010;103:285-290.
4. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11:255-263.
5. Laver NV, McLaughlin ME, Duker JS. Ocular melanoma. Arch Pathol Lab Med. 2010;134:1778-1784.
6. Robertson DM. Changing concepts in the management of choroidal melanoma. Am J Ophthalmol. 2003;136:161-170.
7. Shildkrot Y, Wilson MW. Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. Curr Opin Ophthalmol. 2009;20:504-510.
8. Garcia-Alvarez C, Muinos Y, Saornil MA, et al. Ocular retention in patients with uveal melanoma managed by a multimodality approach [in Spanish]. Arch Soc Esp Oftalmol. 2009;84:145-149.
9. Augsburger JJ, Schneider S, Freire J, Brady LW. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol. 1999;237:558-567.
10. Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005;112:834-840.
11. Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2003;55:867-880.
12. Maia M, Pieramici DJ, Au Eong KG, et al. Non-contiguous recurrence or secondary choroidal melanoma following plaque radiotherapy. Clin Exp Ophthalmol. 2007;35:657-660.
13. Duker JS, Augsburger JJ, Shields JA. Noncontiguous local recurrence of posterior uvealmelanoma after cobalt 60 episcleral plaque therapy. Arch Ophthalmol. 1989;107:1019-1022.
14. Summanen P, Immonen I, Kivela T, et al. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol. 1996;80:732-739.
15. Messmer E, Bornfeld N, Foerster M, Schilling H, Wessing A. Histopathologic findings in eyes treated with a ruthenium plaque for uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 1992;230:391-396.
16. Avery RB, Diener-West M, Reynolds SM, et al. Histopathologic characteristics of choroidal melanoma in eyes enucleated after iodine 125 brachytherapy in the collaborative ocular melanoma study. Arch Ophthalmol. 2008;126:207-212.
17. Saornil MA, Egan KM, Gragoudas ES, et al. Histopathology of proton beam-irradiated vs enucleated uveal melanomas. Arch Ophthalmol. 1992;110:1112-1118.
18. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumorinfiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42:1414-1421.
19. Toivonen P, Makitie T, Kujala E, Kivela T. Macrophages and microcirculation in regressed and partially regressed irradiated choroidal and ciliary body melanomas. Curr Eye Res. 2003;27: 237-245.
20. Bronkhorst IH, Ly LV, Jordanova ES, et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 2011;52:643-650.
21. Maat W, Ly LV, Jordanova ES, et al. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:505-510.
22. Toivonen P, Kivela T. Pigmented episcleral deposits after brachytherapy of uveal melanoma. Ophthalmology. 2006;113: 865-873.
23. Toivonen P, Kivela T. Infiltrating macrophages in extratumoural tissues after brachytherapy of uveal melanoma. Acta Ophthalmol. 2012;90:341-349.
24. Meecham WJ, Char DH, Kaleta-Michaels S. Infiltrating lymphocytes and antigen expression in uveal melanoma. Ophthalmic Res. 1992;24:20-26.
25. de la Cruz PO Jr, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65: 112-115.
26. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889-896.
27. Bronkhorst IH, Vu TH, Jordanova ES, Luyten GP, Burg SH, Jager MJ. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci. 2012;53:5370-5378.
28. Schurmans LR, Blom DJ, De Waard-Siebinga I, et al. Effects of transpupillary thermotherapy on immunological parameters and apoptosis in a case of primary uveal melanoma. Melanoma Res. 1999;9:297-302.
29. Dennaoui J, Bronkhorst IH, Ly LV, et al. Changes in immunological markers and influx of macrophages following trans-scleral thermotherapy of uveal melanoma. Acta Ophthalmol. 2011;89:268-273.
30. Tjho-Heslinga RE, Davelaar J, Kemme HM, et al. Results of ruthenium irradiation of uveal melanomas: the Dutch experience. Radiother Oncol. 1999;53:133-137.
31. Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67:354-361.
32. Jager MJ, van der Pol JP, de Wolff-Rouendaal D, de Jong PT, Ruiter DJ. Decreased expression of HLA class II antigens on human uveal melanoma cells after in vivo X-ray irradiation. Am J Ophthalmol. 1988;105:78-86.
33. Hong M, Puaux AL, Huang C, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 2011;71:6997-7009.
34. Seregard S, Lundell G, Lax I, af Trampe E, Kock E. Tumour cell proliferation after failed ruthenium plaque radiotherapy for posterior uveal melanoma. Acta Ophthalmol Scand. 1997;75: 148-154.
35. Pe'er J, Stefani FH, Seregard S, et al. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study. Br J Ophthalmol. 2001; 85:1208-1212.
36. Chiquet C, Grange JD, Ayzac L, et al. Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas. Br J Ophthalmol. 2000;84:98-102.
37. Kaiserman I, Anteby I, Chowers I, et al. Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma. Br J Ophthalmol. 2004;88:892-895.
38. Shields CL, Bianciotto C, Rudich D, et al. Regression of uveal melanoma after plaque radiotherapy and thermotherapy based on chromosome 3 status. Retina. 2008;28:1289-1295.